143 related articles for article (PubMed ID: 38381994)
1. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,
Shah M; Lingam H; Gao X; Gittleman H; Fiero MH; Krol D; Biel N; Ricks TK; Fu W; Hamed S; Li F; Sun JJ; Fan J; Schuck R; Grimstein M; Tang L; Kalavar S; Abukhdeir A; Pathak A; Ghosh S; Bulatao I; Tilley A; Pierce WF; Mixter BD; Tang S; Pazdur R; Kluetz P; Amiri-Kordestani L
J Clin Oncol; 2024 Apr; 42(10):1193-1201. PubMed ID: 38381994
[TBL] [Abstract][Full Text] [Related]
2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC; Kaklamani VG; Neven P; Streich G; Montero AJ; Forget F; Mouret-Reynier MA; Sohn JH; Taylor D; Harnden KK; Khong H; Kocsis J; Dalenc F; Dillon PM; Babu S; Waters S; Deleu I; García Sáenz JA; Bria E; Cazzaniga M; Lu J; Aftimos P; Cortés J; Liu S; Tonini G; Laurent D; Habboubi N; Conlan MG; Bardia A
J Clin Oncol; 2022 Oct; 40(28):3246-3256. PubMed ID: 35584336
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A; Kaklamani V; Wilks S; Weise A; Richards D; Harb W; Osborne C; Wesolowski R; Karuturi M; Conkling P; Bagley RG; Wang Y; Conlan MG; Kabos P
J Clin Oncol; 2021 Apr; 39(12):1360-1370. PubMed ID: 33513026
[TBL] [Abstract][Full Text] [Related]
4. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Bardia A; Aftimos P; Bihani T; Anderson-Villaluz AT; Jung J; Conlan MG; Kaklamani VG
Future Oncol; 2019 Oct; 15(28):3209-3218. PubMed ID: 31426673
[TBL] [Abstract][Full Text] [Related]
5. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
6. Elacestrant: First Approval.
Hoy SM
Drugs; 2023 Apr; 83(6):555-561. PubMed ID: 37060385
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and pharmacokinetics of elacestrant.
Beumer JH; Foldi J
Cancer Chemother Pharmacol; 2023 Aug; 92(2):157-163. PubMed ID: 37314500
[TBL] [Abstract][Full Text] [Related]
8. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan P; Dilawari A; Osgood C; Feng Z; Bloomquist E; Pierce WF; Jafri S; Kalavar S; Kondratovich M; Jha P; Ghosh S; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
J Clin Oncol; 2023 Apr; 41(11):2108-2116. PubMed ID: 36780610
[TBL] [Abstract][Full Text] [Related]
9. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
10. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.
Rugo HS
Clin Adv Hematol Oncol; 2023 Dec; 21(12):623-632. PubMed ID: 38039056
[TBL] [Abstract][Full Text] [Related]
11. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
13. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP; Bagegni NA; Batist G; Brufsky A; Cristofanilli MA; Damodaran S; Daniel BR; Fleming GF; Gradishar WJ; Graff SL; Grosse Perdekamp MT; Hamilton E; Lavasani S; Moreno-Aspitia A; O'Connor T; Pluard TJ; Rugo HS; Sammons SL; Schwartzberg LS; Stover DG; Vidal GA; Wang G; Warner E; Yerushalmi R; Plourde PV; Portman DJ; Gal-Yam EN
Ann Oncol; 2023 Dec; 34(12):1141-1151. PubMed ID: 38072514
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.
Varella L; Cristofanilli M
Onco Targets Ther; 2023; 16():189-196. PubMed ID: 36993871
[TBL] [Abstract][Full Text] [Related]
15. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A; Mayer I; Winer E; Linden HM; Ma CX; Parker BA; Bellet M; Arteaga CL; Cheeti S; Gates M; Chang CW; Fredrickson J; Spoerke JM; Moore HM; Giltnane J; Friedman LS; Chow Maneval E; Chan I; Jhaveri K
Breast Cancer Res Treat; 2023 Jan; 197(2):319-331. PubMed ID: 36401732
[TBL] [Abstract][Full Text] [Related]
16. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Tolaney SM; Chan A; Petrakova K; Delaloge S; Campone M; Iwata H; Peddi PF; Kaufman PA; De Kermadec E; Liu Q; Cohen P; Paux G; Wang L; Ternès N; Boitier E; Im SA
J Clin Oncol; 2023 Aug; 41(24):4014-4024. PubMed ID: 37348019
[TBL] [Abstract][Full Text] [Related]
17. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
18. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
19. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
20. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti C; De Angelis C; Bianchini G; Malorni L; Giuliano M; Hamilton E; Jeselsohn R; Jhaveri K; Curigliano G; Criscitiello C
Cancer Treat Rev; 2023 Jun; 117():102569. PubMed ID: 37146385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]